News

Published on 22 May 2024 on Zacks via Yahoo Finance

Carlisle (CSL) Divests Interconnect Technologies Business


Article preview image

Carlisle Companies Incorporated CSL recently completed the previously announced divestment of its Carlisle Interconnect Technologies (“CIT”) segment to Amphenol Corporation APH. The transaction was valued at $2.025 billion.Based in Wallingford, CT, Amphenol is a leading designer, manufacturer and marketer of electrical, electronic and fiber optic connectors primarily in the United States and China. Some of the notable products offered by the company are connectors and connector systems, busbars and power distribution systems, among others.Carlisle’s CIT segment is engaged in designing and manufacturing high-performance wire and cable, fiber optic cable, avionics trays, integrated systems as well as complex cable assemblies for applications in the aerospace industry. Also, it provides engineered products for the defense industry that include applications for radar systems, missiles and electronic warfare systems as well as test and measurement solutions.The divestment is in sync with CSL’s Vision 2030 strategy. This move will allow Carlisle to build a concentrated portfolio of construction materials businesses to accentuate its capital allocation approach to investments. Carlisle expects CIT to achieve long-term growth and profitability from this divestiture.It’s worth noting that the company divested its Fluid Technologies segment in October 2023 and the Brake & Friction segment in August 2021 as part of its portfolio enhancement strategy.

Zacks Rank & Price Performance

Carlisle, with a $20.3 billion market capitalization, currently sports a Zacks Rank #1 (Strong Buy). The company is poised to benefit from the growing popularity of reroofing products, solid repair and remodel demand across the building envelope in commercial and residential markets, and synergies from buyouts. Contribution from the Carlisle Operating System and effective pricing actions are other tailwinds.

NYSE.CSL price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Is CSL Limited (ASX:CSL) Trading At A 30% Discount?

Key Insights CSL's estimated fair value is AU$408 based on 2 Stage Free Cash Flow to Equity CSL i...

Simply Wall St. · via Yahoo Finance 10 Jan 2025

Carlisle to Boost Product Portfolio With the Acquisition of ThermaFoam

Carlisle Companies Incorporated CSL recently announced that it has signed a definitive deal to...

Zacks · via Yahoo Finance 24 Dec 2024

Carlisle Buys Plasti-Fab & Enhances its Position in Polystyrene Market

Carlisle Companies Incorporated CSL recently completed the acquisition of the expanded polystyren...

Zacks · via Yahoo Finance 19 Dec 2024

Is It Too Late To Consider Buying Carlisle Companies Incorporated (NYSE:CSL)?

Carlisle Companies Incorporated (NYSE:CSL) saw a double-digit share price rise of over 10% in the...

Simply Wall St. · via Yahoo Finance 8 Dec 2024

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixi...

Zacks · via Yahoo Finance 21 Nov 2024

Decoding Carlisle Companies Inc (CSL): A Strategic SWOT Insight

Robust Revenue Growth: CSL reports a significant increase in revenues, marking a strong financial...

GuruFocus.com · via Yahoo Finance 26 Oct 2024

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine...

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi ...

Benzinga · via AOL 16 Oct 2024

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine...

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi ...

Benzinga · via Yahoo Finance 5 Oct 2024

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's...

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At L...

Benzinga · via Yahoo Finance 30 Sep 2024

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's...

CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase ...

Benzinga · via AOL 30 Sep 2024